Isosorbide-5-mononitrate and isosorbide dinitrate retard in the treatment of coronary heart disease: A multi-centre study

References

• Abshagen U., Spörl-Radun S. First data on effects and pharmacokinetics of isosorbide-5-mononitrate in normal man. Eur J. Clin. Pharmacol 1981; 19: 4231. Abshagen U., Spörl-Radun S. First data on effects and pharmacokinetics of isosorbide-5-mononitrate in normal man. Eur J. Clin. Pharmacol 1981; 19: 423
   PubMed Web of Science ®Google Scholar
• Bidoggia H. J., Cesar J. E., Hirschon A. J., Campo A., Nordaby R. Beneficial effects of isosorbide-5-mononitrate on exercise performance in patients with chronic stable angina pectoris. “International Symposium on Mononitrates, Montreux, Switzerland”, J. N. Cohn, R. 0 Rittinghausen. Springer Verlag, Berlin, Heidelberg, New York 1984; 2012. Bidoggia H. J., Cesar J. E., Hirschon A. J., Campo A., Nordaby R. Beneficial effects of isosorbide-5-mononitrate on exercise performance in patients with chronic stable angina pectoris. “International Symposium on Mononitrates, Montreux, Switzerland”, J. N. Cohn, R. 0 Rittinghausen. Springer Verlag, Berlin, Heidelberg, New York 1984; 201
   Google Scholar
• Danahy D. T., Aronow W. S. Hemodynamics and anti-anginal effects of high dose oral isosorbide dinitrate after chronic use. Circulation 1977; 56: 2053. Danahy D. T., Aronow W. S. Hemodynamics and anti-anginal effects of high dose oral isosorbide dinitrate after chronic use. Circulation 1977; 56: 205
   PubMed Web of Science ®Google Scholar
• De la Balze F. A., Aguilo B., Moreton E., Goransky L., Gurtman A., Arrillaga F., Curante C., Cordero Funes J., Bidoggia H. J. Factores metabólicos y ambientales en la etiopatogenia del infarto de miocardio en personas jovenes. Rev. Argent. Endocrinol. Metabol 1968; 14: 474. De la Balze F. A., Aguilo B., Moreton E., Goransky L., Gurtman A., Arrillaga F., Curante C., Cordero Funes J., Bidoggia H. J. Factores metabólicos y ambientales en la etiopatogenia del infarto de miocardio en personas jovenes. Rev. Argent. Endocrinol. Metabol 1968; 14: 47
   PubMedGoogle Scholar
• Engel H. J., Lichtlen P. R. Beneficial enhancement of coronary flow by nifedipine: comparison with nitroglycerin and beta-blocking agents. Am. J. Med 1981; 71: 6585. Engel H. J., Lichtlen P. R. Beneficial enhancement of coronary flow by nifedipine: comparison with nitroglycerin and beta-blocking agents. Am. J. Med 1981; 71: 658
   PubMed Web of Science ®Google Scholar
• Forman R., Eng C., Kirk E. S. Comparative effect of verapamil and nitroglycerin on collateral blood flow. Circulation 1983; 67: 12046. Forman R., Eng C., Kirk E. S. Comparative effect of verapamil and nitroglycerin on collateral blood flow. Circulation 1983; 67: 1204
   PubMedGoogle Scholar
• Franciosa J. A., Blank R. C., Cohn J. N. Nitrate effects on cardiac output and left ventricular outflow resistance in chronic congestive heart failure. Am. J. Med 1978; 64: 2077. Franciosa J. A., Blank R. C., Cohn J. N. Nitrate effects on cardiac output and left ventricular outflow resistance in chronic congestive heart failure. Am. J. Med 1978; 64: 207
   PubMed Web of Science ®Google Scholar
• Franciosa J. A., Goldsmith S. R., Cohn J. N. Contrasting immediate and long-term effects of isosorbide dinitrate on exercise capacity in congestive heart failure. Am. J. Med., 1980; 69: 5598. Franciosa J. A., Goldsmith S. R., Cohn J. N. Contrasting immediate and long-term effects of isosorbide dinitrate on exercise capacity in congestive heart failure. Am. J 1980;. Med.,69: 559
   PubMed Web of Science ®Google Scholar
• Imhoff P. R., Ott E., Frankhauser P., Chu L. C., Hodler J. Difference in nitroglycerin dose-response in the venous and arterial beds. Eur. J. Clin. Pharmacol 1980; 18: 4559. Imhoff P. R., Ott E., Frankhauser P., Chu L. C., Hodler J. Difference in nitroglycerin dose-response in the venous and arterial beds. Eur. J. Clin. Pharmacol 1980; 18: 455
   PubMed Web of Science ®Google Scholar
• Jansen W., Osterspey A., Fuchs M., Tauchert M., Schell W., Weste S., Hombach V. Hämodynamische Wirkung von 20 mg und 50 mg 5-Isosorbidmononitrat unter akuter and chronischer Therapie. Med. Welt 1982; 33: 175610. Jansen W., Osterspey A., Fuchs M., Tauchert M., Schell W., Weste S., Hombach V. Hämodynamische Wirkung von 20 mg und 50 mg 5-Isosorbidmononitrat unter akuter and chronischer Therapie. Med. Welt 1982; 33: 1756
   PubMedGoogle Scholar
• Markis J. E., Gorlin R., Mills R. M., William R. A., Schweitzer P., Ransil B. J. Sustained effects of orally administered isosorbide dinitrate on exercise performance of patients with angina pectoris. Am. J. Cardiol 1979; 43: 26511. Markis J. E., Gorlin R., Mills R. M., William R. A., Schweitzer P., Ransil B. J. Sustained effects of orally administered isosorbide dinitrate on exercise performance of patients with angina pectoris. Am. J. Cardiol 1979; 43: 265
   PubMed Web of Science ®Google Scholar
• Miller R. R., Vismara L. A., Williams D., Amsterdan E. A., Mason D. T. Pharmacological mechanism of left ventricular unloading in clinical congestive heart failure: differential effects of nitroprusside, phentolamine and nitroglycerin on cardiac function and peripheral circulation. Circ. Res 1976; 39: 12712. Miller R. R., Vismara L. A., Williams D., Amsterdan E. A., Mason D. T. Pharmacological mechanism of left ventricular unloading in clinical congestive heart failure: differential effects of nitroprusside, phentolamine and nitroglycerin on cardiac function and peripheral circulation. Circ. Res 1976; 39: 127
   PubMed Web of Science ®Google Scholar
• Monroe G. R. Myocardial oxygen consumption during ventricular contraction and relaxation. Circ. Res 1964; 14: 29413. Monroe G. R. Myocardial oxygen consumption during ventricular contraction and relaxation. Circ. Res 1964; 14: 294
   PubMed Web of Science ®Google Scholar
• Miiller G., Hacker W., Schneider B. Intra-individual comparison of the action of equal doses of isosorbide-5-endomononitrate, slow-release isosorbide dinitrate and placebo in patients with coronary heart disease. Klin. Wochenschr 1983; 61: 40914. Miiller G., Hacker W., Schneider B. Intra-individual comparison of the action of equal doses of isosorbide-5-endomononitrate, slow-release isosorbide dinitrate and placebo in patients with coronary heart disease. Klin. Wochenschr 1983; 61: 409
   PubMedGoogle Scholar
• Rennak U., Riebesel T., Biamino G. A double-blind crossover study on the effectiveness and possible development of tolerance during long-term therapy with isosorbide-5-mononitrate or isosorbide dinitrate slow-release in coronary artery disease. “International Symposium on Mononitrates, Montreux, Switzerland”, J. N. Cohn, R. 0 Ritting-hausen. Springer Verlag, Berlin, Heidelberg, New York 1985; 14715. Rennak U., Riebesel T., Biamino G. A double-blind crossover study on the effectiveness and possible development of tolerance during long-term therapy with isosorbide-5-mononitrate or isosorbide dinitrate slow-release in coronary artery disease. “International Symposium on Mononitrates, Montreux, Switzerland”, J. N. Cohn, R. 0 Ritting-hausen. Springer Verlag, Berlin, Heidelberg, New York 1985; 147
   Google Scholar
• Rudolph W., Blasini R., Reiniger G. Tolerance development during isosorbide dinitrate treatment. Can it be circumvented?. Z. Kardiol 1983; 72(Suppl. 3)19516. Rudolph W., Blasini R., Reiniger G. Tolerance development during isosorbide dinitrate treatment. Can it be circumvented?. Z. Kardiol 1983; 72(Suppl. 3)195
   PubMedGoogle Scholar
• Steinorth G., Seidel U., Glocke M., Uberbacher H. J. Double-blind crossover study on the anti-anginal efficacy of IS-5-MN and ISDN S.R.: a multicenter trial. “International Symposium on Mononitrates, Montreux, Switzerland, J. N. Cohnand, R. 0 Rittinghausen. Springer Verlag, Berlin, Heidelberg, New York 1985; 27017. Steinorth G., Seidel U., Glocke M., Uberbacher H. J. Double-blind crossover study on the anti-anginal efficacy of IS-5-MN and ISDN S.R.: a multicenter trial. “International Symposium on Mononitrates, Montreux, Switzerland, J. N. Cohnand, R. 0 Rittinghausen. Springer Verlag, Berlin, Heidelberg, New York 1985; 270
   Google Scholar
• Thadani U., Fung H. L., Darke A. C., Parker J. O. Oral isosorbide dinitrate in angina pectoris: comparison of duration of action and dose-response relation during acute and sustained therapy. Am. J. Cardiol 1982; 49: 41118. Thadani U., Fung H. L., Darke A. C., Parker J. O. Oral isosorbide dinitrate in angina pectoris: comparison of duration of action and dose-response relation during acute and sustained therapy. Am. J. Cardiol 1982; 49: 411
   PubMed Web of Science ®Google Scholar
• Thadani U., Manyari D., Parker J. O., Fung H. L. Tolerance to the circulation effects of oral isosorbide dinitrate. Rate of development and cross-tolerance to glyceryl trinitrate. Circulation 1980; 61: 52619. Thadani U., Manyari D., Parker J. O., Fung H. L. Tolerance to the circulation effects of oral isosorbide dinitrate. Rate of development and cross-tolerance to glyceryl trinitrate. Circulation 1980; 61: 526
   PubMed Web of Science ®Google Scholar
• überbacher H. J., Steinorth G., Glocke M., Abshagen U. An open, long-term, multi-centre study of the anti-anginal efficacy and safety of isosorbide-5-mononitrate at low doses in patients with coronary heart disease. Pharmatherapeutica 1983; 3: 33120. überbacher H. J., Steinorth G., Glocke M., Abshagen U. An open, long-term, multi-centre study of the anti-anginal efficacy and safety of isosorbide-5-mononitrate at low doses in patients with coronary heart disease. Pharmatherapeutica 1983; 3: 331
   PubMedGoogle Scholar